The global allergy treatment market is estimated to be valued at USD 21.19 Bn in 2024 and is expected to exhibit a CAGR of 7.2% during the forecast period (2024-2031). The global allergy treatment market has been witnessing significant growth over the past few years owing to the rising prevalence of allergic disorders worldwide. Allergic disorders are caused when the immune system overreacts to environmental allergens such as dust, pollen, mold, etc. According to recent estimates, over 1 billion people globally suffer from allergic rhinitis. Additionally, the rising levels of pollution and changed lifestyle habits have further increased the risk of developing allergies. As a result, there has been a growing demand for effective treatment options such as antihistamines, decongestants, corticosteroids, and allergen immunotherapy for managing the symptoms of various allergic conditions.

Market Dynamics:

The global allergy treatment market is driven by factors such as increasing pollution levels, changing climate conditions, and rising healthcare expenditure in developing nations. However, the lack of awareness about allergy treatment in rural areas and high costs associated with immunotherapy restrain the market growth. The development of novel therapeutic drugs with improved efficacy offers lucrative opportunities in the market. Key players are focusing on R&D to develop advanced treatment regimens for tackling drug resistance issues. However, stringent regulations for approval of new allergy drugs pose a challenge

Key Features of the Study:

• This report provides an in-depth analysis of the global allergy treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global allergy treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Sanofi, Novartis, GSK plc, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Stallergenes Greer, Dermapharm Holding SE, Nicox, Allergy Therapeutics, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, ALK-Abelló A/S, Bausch Health Companies Inc., GLENMARK PHARMACEUTICALS LTD., Perrigo Company plc, and Dr Reddy’s Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global allergy treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global allergy treatment market.

Detailed Segmentation-

• By Type:
  • Eye Allergy
  • Asthma
  • Rhinitis
  • Skin Allergy
  • Food Allergies
  • Others
• By Treatment:
  • Anti-allergy Drugs
  • Immunotherapy
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Novartis
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Hoffmann-La Roche Ltd.
  • Stallergenes Greer
  • Dermapharm Holding SE
  • Nicox
  • Allergy Therapeutics
  • AbbVie Inc. 
  • Teva Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • ALK-Abelló A/S
  • Bausch Health Companies Inc.
  • GLENMARK PHARMACEUTICALS LTD. 
  • Perrigo Company plc
  • Dr Reddy’s Laboratories Ltd.